Skip to main content

Regeneron Pharmaceuticals Q3 FY2026 results

  • REGN · Nasdaq
  • Pharmaceuticals
  • Biotechnology
  • S&P 500
$955.47+0.45%Close 13 Nov 2026 · Market value $102.5B

Regeneron Pharmaceuticals reported revenue of $5.12 billion, up 36.3% from a year earlier, net income of $1.95 billion and diluted earnings per share of $18.45 against $13.62 for the third quarter of fiscal 2026 (the three months to 30 Sep 2026).

From its quarterly report, filed 30 Oct 2026. Compiled and checked by AapWire.

Q3 FY2026 against Q3 FY2025

Three months to 30 Sep 2026, against the three months to 30 Sep 2025. Amounts in USD.

Regeneron Pharmaceuticals Q3 FY2026 results against the year-ago quarter
MeasureQ3 FY2026Q3 FY2025Change
Revenue$5.12B$3.75B+36.3%
Operating income$2.05B$1.03B+99.5%
Operating margin40.0%27.3%+12.7 pts
Net income$1.95B$1.46B+33.5%
Diluted EPS$18.45$13.62+35.5%
Operating cash flow$1.78B$1.62B+10.2%
Capital expenditure$300.2M$201.4M+49.1%
Free cash flow$1.48B$1.42B+4.6%

Operating KPIs for the quarter

Regeneron Pharmaceuticals operating KPIs, Q3 FY2026
KPIQ3 FY2026Change on a year
Collaboration revenue$3.0Bup 52.4%
Net product sales$1.8Bup 13.7%
Libtayo revenue$550.0Mup 50.6%
Lynozyfic revenue$19.0M—
EYLEA HD And EYLEA revenue$1.1Bdown 1.1%
EYLEA HD revenue$698.8Mup 62.3%
EYLEA revenue$399.7Mdown 41.3%
Praluent revenue$81.5Mup 20.4%
Evkeeza revenue$55.5Mup 29.7%

Earlier quarters

Regeneron Pharmaceuticals results, last eight filed quarters
QuarterPeriod endRevenueChange on a yearDiluted EPS
Q3 FY202630 Sep 2026$5.12B+36.3%$18.45
Q2 FY202630 Jun 2026$4.29B+16.7%$12.23
Q1 FY202631 Mar 2026$3.61B+19.0%$6.75
Q4 FY202531 Dec 2025$3.88B+2.5%$7.84
Q3 FY202530 Sep 2025$3.75B+0.9%$13.62
Q2 FY202530 Jun 2025$3.68B+3.6%$12.81
Q1 FY202531 Mar 2025$3.03B−3.7%$7.27
Q4 FY202431 Dec 2024$3.79B+10.3%$8.08

More on Regeneron Pharmaceuticals: financial statements · revenue · earnings per share

REGN's results, as they are filed.

Releases read within minutes, guidance against results, the quarter in its eight-quarter history, and an alert on each new report.